eurogenic inflammation in diabetic polyneuropathy and Charcot neuro-osteoarthropathy: response to intracutaneous Candida albicans - Neurogenic inflammation in diabetes

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 48 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Patients with type 2 diabetes with and without polyneuropathy aged 40-75 years. The presence of polyneuropathy is assessed by means of the Valk score and measurement of the conduction velocity in the n. suralis.
•Patients with type 2 diabetes with a history of Charcot*s disease aged 40-75 years.
•Healthy controls aged 40-75 years.
•Signed informed consent.

•Peripheral arterial disease.
•Active Charcot's disease.
•Renal insufficiency.
•Systemic disease.
•Malignancy.
•(Diabetic) foot ulcer.
•Bacterial infection of an extremity.
•Skin condition of the dorsal aspect of the foot or the medial side of the upper arm.
•Bleeding disorder.
•Use of medication for asthma.
•Impaired immunity.
•Capillary blood glucose < 3 mmol/l or > 20 mmol/l at the time of the study.
•Peripheral oedema.
•Vaccination in the two months prior to study inclusion.
•Chemotherapy or radiation therapy in the twelve months prior to study inclusion.
•Surgery in the two months prior to study inclusion.
•Previous adverse reaction to Candida albicans antigen.
•History of anaphylaxis.
•Acute infection at the time of the study or in the month prior to study inclusion.
•Transfusion in the two months prior to study inclusion.
•Use of immunosuppressants in the two months prior to study inclusion.
•Pregnancy or breastfeeding.

发起方

Medisch Universitair Ziekenhuis Maastricht